Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Jan 10;13(1):e12602.
doi: 10.7759/cureus.12602.

Atypical Neuroleptic Malignant Syndrome in the Setting of Quetiapine Overdose: A Case Report and Review of the Literature

Affiliations
Case Reports

Atypical Neuroleptic Malignant Syndrome in the Setting of Quetiapine Overdose: A Case Report and Review of the Literature

Sheila D Hernandez et al. Cureus. .

Abstract

Neuroleptic malignant syndrome (NMS) is a rare and life-threatening emergency. The condition is largely iatrogenic and is often precipitated by medications such as antipsychotics. First-generation antipsychotics are more likely to cause NMS than second-generation antipsychotics. The literature lacks an objective measure for NMS diagnosis. Instead, the diagnosis relies largely on the recognition of characteristic symptoms in the presence of an inciting medication. Additional challenges exist with concomitant disease processes and toxicities that may distort the clinical picture. Here, we report a case of a 44-year-old Caucasian man who presented with atypical NMS in the setting of quetiapine overdose. The patient remained uncharacteristically afebrile throughout his admission. Although the patient recovered, extended delays in identification and management can contribute to an increased risk of morbidity and mortality.

Keywords: atypical antipsychotic; neuroleptic malignant syndrome; overdose.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Longitudinal Creatine Kinase Levels During Admission
Blue = Patient creatine kinase levels; Orange = Reference values
Figure 2
Figure 2. Longitudinal Creatinine Levels During Admission
Blue = Patient creatinine levels; Orange = Reference values

Similar articles

Cited by

References

    1. Diagnosis and implications in the therapeutic management of patient with afebrile neurolepctic malignant syndrome. Gomes RQ, Dos Santos-Junior A, Dias GA, Cais CF. Oxf Med Case Reports. 2016;2016:67. - PMC - PubMed
    1. Neuroleptic malignant syndrome. Adnet P, Lestavel P, Krivosic-Horber R. Br J Anaesth. 2000;85:129–135. - PubMed
    1. Neuroleptic malignant syndrome: a review for neurohospitalists. Berman BD. Neurohospitalist. 2011;1:41–47. - PMC - PubMed
    1. Atypical neuroleptic malignant syndrome associated with use of clozapine. Leonardo QF, Juliana GR, Fernando CJ. Case Rep Emerg Med. 2017;2017:2174379. - PMC - PubMed
    1. Neuroleptic malignant syndrome: a diagnostic challenge. Ambulkar RP, Patil VP, Moiyadi AV. J Anaesthesiol Clin Pharmacol. 2012;28:517–519. - PMC - PubMed

Publication types

LinkOut - more resources